Strengths and prices
| Strength | Price per vial | Availability | Batch | |
|---|---|---|---|---|
| 15 mg | $25.00 | In stock | — | |
| 20 mg | $30.00 | In stock | HY0722-37 | |
| 30 mg | $45.00 | In stock | 26T10R251836 | |
| 40 mg | $50.00 | In stock | — | |
| 50 mg | $65.00 | In stock | 26T10R151747 | |
| 60 mg | $60.00 | In stock | TR-2607-0086 |
Every vial carries its batch code and a QR that opens the certificate of analysis for that exact batch. No account is needed to read one.
What it is
Tirz-2 is a synthetic peptide of the incretin class that acts at two receptors: GIP and GLP-1.
Identity
| Type | Synthetic acylated peptide, dual receptor agonist |
|---|---|
| Receptors | GIP and GLP-1 |
Tirz-2 is a synthetic acylated peptide of the incretin class with agonist activity at the GIP and GLP-1 receptors. Compounds of this class are single-chain peptides of 39 amino acids built on the sequence of GIP, with aminoisobutyric acid substituted at positions 2 and 13 to resist cleavage by DPP-4, a C20 fatty diacid attached through a linker to the lysine at position 20 so that the peptide binds albumin, and an amidated C-terminus. The compound's generic name, formula and CAS number are left off this page by design. It is supplied as a white lyophilized powder in a sealed vial.
What the published research covers
Compounds of this class have been studied in large phase 3 clinical trials, with results published in peer-reviewed journals.
Tirz-2 belongs to the dual-agonist branch of the incretin class: peptides that act at both the GIP and GLP-1 receptors. The first dual agonist of this type was disclosed by its sponsor in 2018 as a fatty-acid-modified peptide tested in receptor assays, in mice and in a phase 1 trial of 142 subjects, where the higher treatment groups showed fasting glucose about 43 to 49 mg/dL lower and body weight about 2 kg lower than placebo (Coskun, 2018). Later pharmacology described it as an imbalanced agonist, engaging the GIP receptor more fully than the GLP-1 receptor, and as a biased one, favoring cAMP signaling over beta-arrestin recruitment (Willard, 2020).
The human data are large sponsor-run phase 3 trials. A 40-week monotherapy trial in type 2 diabetes was the first (Rosenstock, 2021). A 40-week trial in 1,879 patients compared the compound with a GLP-1 receptor agonist and reported HbA1c reductions of 2.01 to 2.30 percentage points against 1.86, with 1.9 to 5.a reduction in body weight about 5 kg greater (Frias, 2021). A 72-week trial in adults with obesity reported graded reductions in body weight across its treatment groups against placebo (Jastreboff, 2022). A 2024 trial reported fewer apnea events in adults with obstructive sleep apnea and obesity (Malhotra, 2024). Gastrointestinal adverse events were the most common finding in every trial.
A compound of this class is approved in the United States as a prescription product; the published studies concern that product, made and tested by its sponsor, not research-grade material. Open questions include outcomes beyond three years, the course after stopping, and how the receptor bias translates into effect.
Regulatory status
A compound of this class exists as an FDA-approved prescription product. This material is not that product and is supplied for laboratory research only.
Testing and documentation
Identity is confirmed by mass spectrometry and purity by HPLC. The certificate of analysis for the batch is reachable from the code on the vial.
Questions laboratories ask
- What strengths is Tirz-2 offered in?
- Vials of 5, 10, 15, 20, 30, 40, 45, 50 and 60 mg, as listed on the product page. The amount is on the vial label and on the certificate of analysis for the batch.
- Is Tirz-2 the approved prescription drug?
- No. A compound of this class exists as an FDA-approved prescription product made by its sponsor. Tirz-2 is not that product; it is a research peptide supplied for laboratory research only, under the Research Use Agreement.
- Is there a certificate of analysis for each batch?
- Yes. Every batch is tested by an independent laboratory: identity by mass spectrometry and purity by HPLC. The QR code on the vial opens the certificate for that exact batch; no account is needed to read it.
- How does it ship?
- From Montana, the next business day for an order paid by card, by FedEx or USPS. We ship to addresses in the United States only and not to freight forwarders.
References
- Coskun T et al. (2018). LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Molecular Metabolism. PubMed 30473097
- Willard FS et al. (2020). Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight. PubMed 32730231
- Rosenstock J et al. (2021). Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. PubMed 34186022
- Frias JP et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. PubMed 34170647
- Jastreboff AM et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. PubMed 35658024
- Malhotra A et al. (2024). Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. New England Journal of Medicine. PubMed 38912654
How it ships
Ordering
Ordering needs an account. A retail account opens as soon as you request it and costs nothing. You pay by card at checkout, or by invoice before the order ships. A wholesale account is reviewed before it opens.
Research use only
This product is a research chemical sold solely for in-vitro laboratory research by qualified persons. It is not a drug, food, supplement or cosmetic, has not been evaluated by the FDA, and must not be administered to any person or animal. Read the full agreement